BioVector® TALL-104 人急性T淋巴细胞白血病细胞株

BioVector® TALL-104 Human Acute T Lymphoblastic Leukemia Cell Line

第一部分 中文说明

一 产品基本信息与遗传学背景

• 细胞名称 BioVector® TALL-104 人急性T淋巴细胞白血病细胞

• 系统学 Accession Cellosaurus CVCL 1729

• 保藏机构货号 ATCC CRL 11386

• 物种来源 人类 Homo sapiens

• 组织与疾病背景 该细胞株建立于一名患有急性T淋巴细胞白血病的儿童患者的外周血。尽管起源于恶性T细胞白血病，但在体外经特定细胞因子诱导长期维持培养后，该细胞展现出极其独特且高效的非特异性细胞毒性杀伤表型。

• 主要表面标志物与表型

  • 表现为 CD3阳性、CD8阳性、CD56阳性、CD2阳性 和 TCR Alpha/Beta阳性。

  • 核心生物学特征 缺乏 CD4、细胞毒性T细胞抗原-4 以及传统的 CD16 表达。它兼具细胞毒性T淋巴细胞与自然杀伤细胞的杀伤特性，被称为具有广谱抗肿瘤活性的MHC非限制性杀伤细胞。

• 生物安全级别 1级。

二 细胞形态学与特殊培养环境

• 形态学特征 展现典型的淋巴母细胞样特征，细胞呈圆形，在悬浮状态下生长，通常会聚集形成大小不一的细胞簇。

• 生长模式 悬浮生长。

• 倍增时间 在添加足量重组人白介素-2的完全培养基中，细胞增殖活跃。

• 标准完全培养基配方

  • 基础培养基 BioVector® Iscove's Modified Dulbecco's Medium，即IMDM培养基。

  • 维持添加

    • 20% BioVector® 优质胎牛血清。

    • 必需生长因子 重组人白介素-2，最终浓度为 100 U/mL。注意：缺乏白介素-2将导致该细胞迅速停止增殖并发生凋亡。

• 物理培养参数 37摄氏度恒温、5% 二氧化碳、空气饱和湿度。

三 细胞传代与复苏标准操作步骤

1. 常规传代操作

   • 当细胞密度达到每毫升 8.0乘以10的5次方 至 1.5乘以10的6次方 个细胞，且细胞簇显著增大时需要进行传代。

   • 将细胞悬液转移至离心管中，以 150 g离心 5到8分钟，弃去旧培养基。

   • 用新鲜配制、预热并含有 100 U/mL 重组人白介素-2 的 BioVector® 完全培养基重悬细胞。

   • 推荐接种密度 维持在每毫升 2.0乘以10的5次方 至 3.0乘以10的6次方 个细胞。不建议过度稀释细胞，否则会延长其适应期。传代比例通常为 1比2 至 1比3，每周需要补充或更换培养基 2到3次。

2. 冻存细胞复苏

   • 从液氮中取出冷冻管，立即投入 37摄氏度 BioVector® 水浴锅中快速摇动使其融化，控制在 2分钟内。

   • 将解冻的细胞悬液移至含 9.0 mL 预热基础培养基的离心管中，以 150 g离心 5分钟以去除残留的二甲基亚砜。

   • 弃去上清，加入配制好的 BioVector® 完全培养基重悬接种。

四 核心科研应用方向

1. 肿瘤免疫治疗与效靶杀伤实验 BioVector® TALL-104 广泛用作研究抗肿瘤细胞毒性机制的标准效应细胞。它能高效杀伤多种同种异体及异种的肿瘤靶细胞，且由于其杀伤活性不受 MHC 限制，常被用于过继免疫治疗的临床前安全性与有效性评估。

2. NK/T 细胞活化与细胞因子释放网络研究 用于探索在不同共刺激信号或新型小分子药物干预下，高效杀伤性 T 细胞分泌干扰素、肿瘤坏死因子及颗粒酶和穿孔素的转录调控机制。

3. 新型双特异性抗体药效学评价 在开发靶向 T 细胞表面 CD3 或 CD8 的双特异性或多特异性抗体时，该细胞株是理想的体外靶向桥接杀伤验证模型。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Cell Line Name BioVector® TALL-104

• Cellosaurus Accession CVCL 1729

• Repository Catalog Number ATCC CRL 11386

• Species Origin Human Homo sapiens

• Tissue and Disease Background Established from the peripheral blood of a pediatric patient diagnosed with Acute T Lymphoblastic Leukemia. Following long term in vitro conditioning with specific cytokines, this line stabilized into a highly unique MHC nonrestricted cytotoxic killer phenotype despite its leukemic lineage.

• Surface Marker Profile

  • Authenticated as CD3 positive, CD8 positive, CD56 positive, CD2 positive, and TCR Alpha/Beta positive.

  • Key Immunological Features Lacks expression of CD4, CTLA-4, and traditional CD16. It bridges the functional attributes of both Cytotoxic T Lymphocytes and Natural Killer cells, acting as a broad spectrum anti tumor effector model.

• Biosafety Level BSL-1.

II Morphological Attributes and Cultivation Media

• Morphology Displays characteristic lymphoblast like round features. Cells expand in suspension and regularly pack into multi cellular clusters of varying sizes.

• Growth Mode Suspension Growth.

• Standard Complete Growth Medium Formulation

  • Basal Medium BioVector® Iscove's Modified Dulbecco's Medium, which is IMDM.

  • Routine Maintenance Supplements

    • 20% premium BioVector® Fetal Bovine Serum.

    • Essential Cytokine Supplement Recombinant Human Interleukin-2 at a final concentration of 100 U/mL. Note The absence of rhIL-2 results in rapid growth arrest and autologous apoptosis.

• Physical Incubation Thresholds Regulated strictly at 37 degrees Celsius under an atmospheric layer of 5% Carbon Dioxide and saturated air humidity.

III Subculturing and Thawing Protocols

1. Routine Passaging Schedule

   • Initiate subculturing when the viable cell concentration reaches 8.0乘以10的5次方 to 1.5乘以10的6次方 cells per mL and clusters become large and dense.

   • Transfer the suspension into a sterile centrifuge tube, pellet at 150 g for 5 to 8 minutes, and aspirate the exhausted medium.

   • Resuspend the cell pellet in freshly prepared, pre warmed BioVector® complete growth medium enriched with 100 U/mL rhIL-2.

   • Recommended Seeding Density Seed fresh cultures at 2.0乘以10的5次方 to 3.0乘以10的5次方 cells per mL. Avoid over diluting the biomass to circumvent prolonged lag phases. The standard split ratio ranges from 1比2 to 1比3, with medium replenishment required 2 to 3 times per week.

2. Cryovial Thawing and Recovery

   • Retrieve the cryovial from liquid nitrogen storage and submerge it immediately into a 37 degrees Celsius BioVector® water bath with continuous agitation until liquefied within 2 minutes.

   • Transfer the mixture into a centrifuge tube containing 9.0 mL of pre warmed basal medium and spin at 150 g for 5 minutes to eliminate DMSO residues.

   • Decant the supernatant, gently loosen the pellet, and re establish the culture in complete BioVector® medium containing 20% FBS and 100 U/mL rhIL-2.

IV Strategic Research Applications

1. Tumor Immunotherapy and Effector to Target Cytotoxicity Assays BioVector® TALL-104 is widely deployed as a premier reference effector cell line to evaluate non MHC restricted anti tumor actions. It effectively lyses a broad array of allogeneic and xenogeneic malignant targets and serves as an in vitro pilot benchmark for adoptive immunotherapy modeling.

2. NK/T Cell Activation Kinetics and Degranulation Networks Utilized to investigate transcriptional and secretory mechanisms behind Interferon Gamma, Tumor Necrosis Factor Alpha, Granzymes, and Perforin release under stimulation by novel small molecule agonists or checkpoint blockers.

3. Evaluation of Bispecific Antibodies Acts as an excellent stable effector model for validating the structural bridge and targeted lysis potential of new bispecific or multi specific antibody formats engineered to engage CD3 or CD8 molecules.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net